Hard to call at this point for several reasons. Political pressure in the US could impede a tax inversion. Moreover, AGN's sale of its generic-drug business to TEVA may encounter pushback from antitrust regulators, and PFE probably wouldn't pursue a merger with AGN unless AGN were able to consummate the TEVA deal.
News 
Market Data 
Discover 
